Genelux Corporation (GNLX)
GNLX Stock Price Chart
Explore Genelux Corporation interactive price chart. Choose custom timeframes to analyze GNLX price movements and trends.
GNLX Company Profile
Discover essential business fundamentals and corporate details for Genelux Corporation (GNLX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jan 2023
Employees
24.00
Website
https://www.genelux.comCEO
Thomas D. Zindrick
Description
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
GNLX Financial Timeline
Browse a chronological timeline of Genelux Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.20.
Earnings released on 7 May 2026
EPS came in at -$0.20 falling short of the estimated -$0.18 by -11.11%.
Earnings released on 19 Mar 2026
EPS came in at -$0.24 falling short of the estimated -$0.22 by -9.09%, while revenue for the quarter reached $8.00k , meeting expectations.
Earnings released on 5 Nov 2025
EPS came in at -$0.21 surpassing the estimated -$0.23 by +8.70%.
Earnings released on 7 Aug 2025
EPS came in at -$0.20 surpassing the estimated -$0.22 by +9.09%.
Earnings released on 6 May 2025
EPS came in at -$0.21 surpassing the estimated -$0.24 by +12.50%.
Earnings released on 28 Mar 2025
EPS came in at -$0.26 falling short of the estimated -$0.17 by -52.94%, while revenue for the quarter reached $452.00k .
Earnings released on 14 Nov 2024
EPS came in at -$0.19 matching the estimated -$0.19.
Earnings released on 14 Aug 2024
EPS came in at -$0.22 falling short of the estimated -$0.19 by -15.79%.
Earnings released on 9 May 2024
EPS came in at -$0.29 falling short of the estimated -$0.23 by -26.09%, while revenue for the quarter reached $8.00k .
Earnings released on 29 Mar 2024
EPS came in at -$0.25 falling short of the estimated -$0.21 by -19.05%, while revenue for the quarter reached $1.46m .
Earnings released on 14 Nov 2023
EPS came in at -$0.20 falling short of the estimated -$0.12 by -66.67%.
Earnings released on 14 Aug 2023
EPS came in at -$0.23 falling short of the estimated -$0.15 by -53.33%.
Earnings released on 15 May 2023
EPS came in at -$0.53 falling short of the estimated -$0.16 by -230.89%, while revenue for the quarter reached $170.00k , meeting expectations.
Earnings released on 26 Jan 2023
EPS came in at -$0.13 surpassing the estimated -$0.17 by +22.12%, while revenue for the quarter reached $68.00k .
Earnings released on 30 Sept 2022
EPS came in at $0.16 , while revenue for the quarter reached $11.00m .
Earnings released on 30 Jun 2022
EPS came in at -$0.13 .
Earnings released on 31 Mar 2022
EPS came in at -$0.13 .
Earnings released on 31 Dec 2021
EPS came in at -$0.12 .
Earnings released on 30 Sept 2021
EPS came in at -$0.14 .
GNLX Stock Performance
Access detailed GNLX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
